Recent

% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, AŞ Message Board

  • weightbayou weightbayou Jun 29, 2013 1:44 PM Flag

    Novartis is the collaborator. A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic

    A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia
    This study is currently recruiting participants.
    Verified June 2013 by NCIC Clinical Trials Group
    Sponsor:
    NCIC Clinical Trials Group
    Collaborators:
    Novartis Pharmaceuticals
    previously: Astex Pharmaceuticals
    Information provided by (Responsible Party):
    NCIC Clinical Trials GroupClinicalTrials.gov Identifier:
    NCT01627054
    First received: June 21, 2012
    Last updated: June 19, 2013
    Last verified: June 2013
    History of Changes